Agile Therapeutics Inc. (AGRX)
NASDAQ: AGRX
· Real-Time Price · USD
1.51
0.05 (3.42%)
At close: Aug 22, 2024, 9:58 PM
Agile Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 5.58M | 5.72M | 3.61M | 6.66M | 5.5M | 3.81M | 4M | 3M | 2.13M | 1.76M | 1.51M | 1.29M | 1.19M | 116K |
Cost of Revenue | 1.5M | 1.68M | 2.19M | 2.48M | 2.31M | 2M | 1.65M | 1.43M | 2.23M | 1.53M | 5.7M | 2.71M | 1.15M | 1.16M |
Gross Profit | 4.08M | 4.04M | 1.42M | 4.18M | 3.2M | 1.81M | 2.34M | 1.58M | -105K | 234K | -4.19M | -1.42M | 40K | -1.04M |
Operating Income | -2.75M | -2.76M | -4.05M | -4M | -5.13M | -6.71M | -6.88M | -7.59M | -11.4M | -15.57M | -22.36M | -15.77M | -16.65M | -16.22M |
Interest Income | 28K | 23K | 17K | 13K | 15K | 33K | 30K | 46K | 2K | 1K | 1K | 1K | 7K | 16K |
Pretax Income | -11.87M | 1.28M | -4.47M | -799K | -3.81M | -5.39M | -3.93M | -19.67M | -12.22M | -16.44M | -23.36M | -16.77M | -17.64M | -17.13M |
Net Income | -11.87M | 1.28M | -4.47M | -799K | -3.81M | -3.61M | -13.28M | -22.05M | -12.22M | -11.77M | -23.36M | -16.77M | -17.64M | -17.13M |
Selling & General & Admin | 6.29M | 6.3M | 5.42M | 7.48M | 7.62M | 7.75M | 8.87M | 8.38M | 10.44M | 14.55M | 16.52M | 12.76M | 15.83M | 13.06M |
Research & Development | 538K | 495K | 54K | 705K | 703K | 763K | 352K | 788K | 856K | 1.26M | 1.66M | 1.59M | 862K | 2.11M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.83M | 6.79M | 5.47M | 8.19M | 8.32M | 8.52M | 9.22M | 9.16M | 11.29M | 15.81M | 18.17M | 14.35M | 16.69M | 15.18M |
Interest Expense | n/a | 185K | 305K | 341K | 372K | 402K | 432K | 1M | 823K | 872K | 999K | 999K | 993K | 922K |
Selling & Marketing Expenses | 3.78M | 3.68M | 3.73M | 4.8M | 4.57M | 4.67M | 6.84M | 5.56M | 7.41M | 10.55M | 12.67M | 9.39M | 11.71M | 9.16M |
Cost & Expenses | 8.32M | 8.47M | 7.67M | 10.66M | 10.63M | 10.52M | 10.87M | 10.59M | 13.52M | 17.33M | 23.87M | 17.06M | 17.84M | 16.34M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | -1.78M | 9.35M | 2.38M | 7.05M | -4.67M | 1M | 1K | 7K | 16K |
Shares Outstanding (Basic) | 6.86M | 4.63M | 2.96M | 2.95M | 1.77M | 912.04K | 824.65K | 739.96K | 90.2K | 62.3K | 58.36K | 46.59K | 44.35K | 43.81K |
Shares Outstanding (Diluted) | 6.86M | 4.63M | 2.96M | 2.95M | 1.77M | 912.04K | 824.65K | 739.96K | 90.2K | 62.3K | 58.96K | 46.88K | 44.35K | 43.81K |
EPS (Basic) | -1.73 | 0.28 | -1.51 | -0.27 | -2.15 | -3.96 | -16.1 | -29.8 | -135.46 | -188.9 | -400.22 | -360.01 | -397.71 | -390.94 |
EPS (Diluted) | -1.73 | 0.28 | -1.51 | -0.27 | -2.15 | -3.96 | -16.1 | -29.8 | -135.46 | -188.9 | -396.18 | -357.78 | -397.71 | -390.93 |
EBITDA | -2.75M | -2.63M | -3.94M | -360K | -3.34M | -4.89M | -6.85M | -7.32M | -3.75M | -13.6M | -21.78M | -15.22M | -16.09M | -15.66M |
EBIT | -11.87M | 1.47M | -4.17M | -458K | -3.44M | -4.99M | 18.67M | -4.93M | -4.34M | -14.19M | -22.36M | -15.77M | -16.64M | -16.21M |
Depreciation & Amortization | n/a | 103K | 100K | 98K | 95K | 93K | 91K | 262K | 593K | 588K | 575K | 552K | 550K | 546K |